

A u g u s t 1 0 , 2 0 2 2

IPR2021-00880, -00881

U.S. Patent Nos. 9,669,069 & 9,254,338

REGENERON[®]

Overview

- VEGF Trap-Eye: All Grounds, All Claims
- IPR2021-00880—U.S. Patent No. 9,669,069
 - Ground 4 – All Claims: No Anticipation or Obviousness Based on Dixon Disclosure of VIEW Dosing Regimen
 - Ground 5 – Claim 8: No Anticipation or Obviousness Based on Heier- of Mitchell or Dixon
- IPR2021-00881—U.S. Patent No. 9,234,338
 - Claim Construction
 - Grounds 1-5 – All Claims: No Anticipation Based on Lack of “Treatment
 - Ground 6 – All Claims: No Obviousness Based on Prospective VIEW Regimen



VEGF Trap-Eye

3

Petitioner's Grounds Do Not Disclose the Recited Amino Acid or Nucleic Acid Sequences

Drug Evaluation

Expert Opinion

VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration

James A Dixon, Scott CN Oliver¹, Jeffrey L Olson & Narsish Mandava
University of Colorado Denver, Health Sciences Center, Department of Ophthalmology, 1675 North Aurora Avenue, PO Box 6516, Mail Stop F-751, Aurora, CO 80045-2516

Background: Age-related macular degeneration (AMD) is a leading cause of blindness in the developed world. Although 90% of patients with AMD are aged 50 years and older, neovascular AMD accounts for the vast majority of cases. Until recently, the treatment of neovascular AMD. The use of anti-VEGF agents, such as ranibizumab and bevacizumab, a number of studies have shown that VEGF Trap-Eye is a safe and effective treatment for neovascular AMD. Two Phase III clinical trials of VEGF Trap-Eye for neovascular AMD are currently underway. These studies will provide vital insight into the clinical applicability of VEGF Trap-Eye as a treatment for neovascular AMD.

Introduction: VEGF Trap-Eye is a fusion protein consisting of VEGF-A and PlGF1, which both play a part in the growth of new blood vessels.

Conclusion: VEGF Trap-Eye is a safe and effective treatment for neovascular AMD. Two Phase III clinical trials of VEGF Trap-Eye for neovascular AMD are currently underway. These studies will provide vital insight into the clinical applicability of VEGF Trap-Eye as a treatment for neovascular AMD.

informa healthcare

Mylan Exhibit 1006
Mylan v. Regeneron, IPR2021-00880
Page 1

Dixon Ex.1006

COVER STORY

Intravitreal VEGF Trap for AMD: An Update

The CLEAR-IT 2 Extension Study was presented at the Association for Research in Vision and Ophthalmology (ARVO) earlier this year. The results of the initial CLEAR-IT 2 as well as the extension stage.

Figure 1: VEGF Trap-Eye is a fusion protein designed to bind all forms of the proteins VEGF-A and PlGF1, which both play a part in abnormal growth of new blood vessels.

Mylan Exhibit 1020
Mylan v. Regeneron, IPR2021-00880
Page 1

Heier-2009 Ex.1020

REGENERON

Bayer and Regeneron Extend Development Program for CRVO

April 30, 2009
 Bayer and Regeneron Extend Development Program for CRVO to start in the second half of this year. BERLIN and TARRYTOWN, N.Y., April 30 (PRNewswire) - Bayer AG and Regeneron Pharmaceuticals, Inc. today announced that the companies are extending their global development program for the treatment of central vein occlusion (CRVO) with VEGF Trap-Eye. The Phase 3 program in CRVO will consist of two, multicenter, randomized, controlled studies. Enrollment in the wet AMD and DME studies is expected to start in the second half of 2009.

Mylan Exhibit 1006
Mylan v. Regeneron, IPR2021-00880
Page 1

Regeneron Ex.1006

Petitioner's Grounds Do Not Disclose the Recited Acid or Nucleic Acid Sequences

REGENERON
May 8, 2008

Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration

International study to evaluate efficacy and safety in treating a leading cause of blindness

Leverkusen, Germany, Montville, NJ and Tarrytown, NY, May 8, 2008 - Bayer HealthCare AG and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the first patient has been dosed in the VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the form of Age-related Macular Degeneration (wet AMD), a leading cause of blindness in adults.

VIEW 2 (VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD) will enroll approximately 200 patients in 10 to 200 centers in Europe, Asia Pacific, Japan and Latin America. The first Phase 3 trial, VIEW 1, was completed in 2007 in the United States and Canada. Both VIEW 1 and VIEW 2 are designed to evaluate the safety and efficacy of VEGF Trap-Eye administered by intravitreal injection, at dosing intervals of 4 and 8 weeks, in patients with wet AMD. The primary endpoints are visual acuity endpoints and anatomical endpoints, including retinal thickness. Secondary endpoints include the proportion of patients who maintain vision at the end of one year, compared to ranibizumab patients. Visual acuity is defined as the total number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, a standard chart used in research to measure visual acuity. Maintenance of vision is defined as losing fewer than three lines (equivalent to 15 letters) on the ETDRS chart. Key secondary endpoints include the mean change from baseline in visual acuity as measured by ETDRS and the proportion of patients who gained at least 15 letters of vision at week 52.

Wet AMD accounts for about 90 percent of all severe AMD. In wet AMD, abnormal blood vessels in the eye leak fluid and blood into the macula, the area of the eye responsible for central vision with continued progression. This can lead to a rapid loss of central vision.

"Results from the Phase 2 study have shown that VEGF Trap-Eye significantly reduce retinal thickness and improve vision," said Kamel Malk, MD, PhD, President of Regeneron. "The Phase 3 clinical program will provide additional data to further evaluate the safety and efficacy of VEGF Trap-Eye in different dosing regimens."

"New therapies are still needed for the treatment of wet AMD," said George D. Vancopoulos, M.D., Ph.D., President of Bayer HealthCare. "The Phase 3 clinical program will provide additional data to further evaluate the safety and efficacy of VEGF Trap-Eye in different dosing regimens."

Bayer HealthCare and Regeneron are jointly developing VEGF Trap-Eye for treatment of wet AMD, diabetic macular edema and other eye diseases. Once approved, Bayer HealthCare will market VEGF Trap-Eye under the name Eylea. Regeneron will continue to be an equal partner in the development of VEGF Trap-Eye. Regeneron maintains an ownership stake in the company. VIEW 2 primary analysis results are anticipated in 2011.

The primary endpoint of the study is the proportion of patients treated with VEGF Trap-Eye who maintain vision at the end of one year, compared to ranibizumab patients. Visual acuity is defined as the total number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) chart, a standard chart used in research to measure visual acuity. Maintenance of vision is defined as losing fewer than three lines (equivalent to 15 letters) on the ETDRS chart. Key secondary endpoints include the mean change from baseline in visual acuity as measured by ETDRS and the proportion of patients who gained at least 15 letters of vision at week 52.

Phase 2 Clinical Data

In a Phase 2 trial in 157 patients, announced in October 2007 at the Retina Society Conference in Boston, VEGF Trap-Eye met both primary and secondary key endpoints: a statistically significant reduction in retinal thickness (a measure of disease)

Mylan Exhibit 1013
Mylan v. Regeneron, IPR2021-00881
Page 1

Regeneron (8-May-2008)
Ex.1013

177020 U.S. National Library of Medicine
History of Changes for Study: NCT00509795
ClinicalTrials.gov archive

History of Changes for Study: NCT00509795
Vascular Endothelial Growth Factor(VEGF)Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) (VIEW1)

Study Record Versions

Version	A	B	Submitter
1			
2			

Mylan Exhibit 1014
Mylan v. Regeneron, IPR2021-00881
Page 1

NCT-795 Ex.1014

1099500 U.S. National Library of Medicine
History of Changes for Study: NCT00509795
ClinicalTrials.gov archive

History of Changes for Study: NCT00509795
VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD) (VIEW2)

Study Record Versions

Version	A	B	Submitter
1			
2			
3			

NCT-795 Ex.1014

NCT-795 Ex.1014

5

881 POR at 25-26; 881 Sur-reply at 14; Ex.2129 at 109:15-110:3; Ex.2130 at 341:13-16; Ex.2049 at Section IX; Ex.2048 at Section X; Ex.1114

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.